文献速递浆细胞疾病MDS 与骨髓增殖性肿瘤

新诊断多发性骨髓瘤患者发育异常造血的生物学与临床意义

Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
PubMed 文献 · Blood · 2020-01-01

本研究采用多维流式细胞术前瞻性筛查285例新诊断多发性骨髓瘤(MM)患者的骨髓MDS相关表型异常(MDS-PA),并在1252例患者中分析单核细胞MDS-PA的临床意义。11.6%的患者存在MDS-PA,其与克隆性造血相关,且独立关联更差的无进展生存和总生存。

要点

  • 新诊断MM中11.6%(33/285)经多维流式细胞术检出MDS相关表型异常。
  • MDS-PA阳性患者克隆性造血比例50% vs 阴性22%,TET2和NRAS最常见。
  • 单核细胞MDS-PA独立关联更差的无进展生存(HR 1.5)和总生存(HR 1.7)。

核心结论

  • 新诊断MM患者存在发育异常造血,具有生物学和临床意义,可用经济有效的多维流式细胞术以中等灵敏度筛查。

研究设计与样本

  • 前瞻性筛查285例入组PETHEMA/GEM2012MENOS65试验(#NCT01916252)的新诊断MM患者骨髓MDS-PA。
  • 在4项PETHEMA/GEM方案入组的1252例患者中分析单核细胞MDS-PA的临床意义。
  • 对67例患者的CD34+祖细胞及发育异常谱系进行MDS复发突变基因的bulk和单细胞靶向测序。
  • 在86/285例患者中评估诊断时及自体移植后MDS-PA的动态变化。

主要发现

  • 诊断时33/285例(11.6%)存在MDS-PA。
  • 67例测序中,MDS-PA阳性者克隆性造血13/26(50%),阴性者9/41(22%);TET2和NRAS突变最常见。
  • 86例动态评估中,69/86(80%)的MDS-PA在诊断时阳性者持续存在、阴性者保持缺失。
  • 大剂量治疗后MDS相关突变罕见出现。
  • MDS-PA阳性患者造血及肿瘤微环境中T调节细胞分布改变。

关键数值与推荐

  • MDS-PA阳性率11.6%(33/285)。
  • 克隆性造血:MDS-PA阳性50%(13/26) vs 阴性22%(9/41)。
  • MDS-PA持续或保持缺失:80%(69/86)。
  • 无进展生存HR 1.5(P=.02);总生存HR 1.7(P=.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Risk of developing myelodysplastic syndrome (MDS) is significantly increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, suggesting that it is therapy independent. However, the incidence and sequelae of dysplastic hematopoiesis at diagnosis are unknown. Here, we used multidimensional flow cytometry (MFC) to prospectively screen for the presence of MDS-associated phenotypic alterations (MDS-PA) in the bone marrow of 285 patients with MM enrolled in the PETHEMA/GEM2012MENOS65 trial (#NCT01916252). We investigated the clinical significance of monocytic MDS-PA in a larger series of 1252 patients enrolled in 4 PETHEMA/GEM protocols. At diagnosis, 33 (11.6%) of 285 cases displayed MDS-PA. Bulk and single-cell-targeted sequencing of MDS recurrently mutated genes in CD34+ progenitors (and dysplastic lineages) from 67 patients revealed clonal hematopoiesis in 13 (50%) of 26 cases with MDS-PA vs 9 (22%) of 41 without MDS-PA; TET2 and NRAS were the most frequently mutated genes. Dynamics of MDS-PA at diagnosis and after autologous transplant were evaluated in 86 of 285 patients and showed that in most cases (69 of 86 [80%]), MDS-PA either persisted or remained absent in patients with or without MDS-PA at diagnosis, respectively. Noteworthy, MDS-associated mutations infrequently emerged after high-dose therapy. Based on MFC profiling, patients with MDS-PA have altered hematopoiesis and T regulatory cell distribution in the tumor microenvironment. Importantly, the presence of monocytic MDS-PA at diagnosis anticipated greater risk of hematologic toxicity and was independently associated with inferior progression-free survival (hazard ratio, 1.5; P = .02) and overall survival (hazard ratio, 1.7; P = .01). This study reveals the biological and clinical significance of dysplastic hematopoiesis in newly diagnosed MM, which can be screened with moderate sensitivity using cost-effective MFC.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Maia C, Puig N, Cedena MT, et al. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma. Blood. 2020. PMID: 32299093. doi:10.1182/blood.2019003382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。